As it turns out, Amgen (Nasdaq:AMGN) didn't have to stretch too far to seal the deal for oncology biotech company Onyx Pharmaceuticals (Nasdaq:ONXX). While Amgen's initial bid of $120 per Onyx share set off a nearly two-month auction process, in the end it took only an extra $5 per share to complete the deal as there was apparently only passing interest from other Big Pharma players to pay up for Onyx's portfolio of oncology drugs. All in all, while it's a worthwhile deal that helps patch over some near-term growth concerns for Amgen, it's unlikely to be a transformative deal.
The Deal
Amgen and Onyx announced that the two companies had reached a definitive agreement by which Amgen will acquire Onyx for $125 per share in cash. At that price, Amgen is paying an enterprise value of just under $10 billion and a premium of over 45% to the share price before word first broke that Onyx was receiving indications of interest.

SEE: What Makes An M&A Deal Work?
Amgen will be financing this deal with over $8 billion in bank loans priced at LIBOR plus 104bp. The key drug to the deal, multiple myeloma drug Kyprolis, is already approved by the FDA and the sales of the drug (coupled with cutting redundant expenses at Onyx) should lead to Amgen seeing accretion from the deal in 2015.
Advancing The Ball, But Not Changing The Game
While it's possible that Onyx has a hidden gem in preclinical research, this deal looks more like an incremental step forward for Amgen than a transformative deal that will fundamentally change the company's trajectory. In particular, this deal for Onyx will help Amgen get through a challenging growth gap in the 2014-2016 period and better leverage its existing sales and manufacturing infrastructure.

Said differently, Amgen investors should not look at this as a deal on par with Johnson & Johnson's (NYSE:JNJ) acquisition of Cougar or Celgene's (Nasdaq:CELG) acquisition of Abraxis. What's more, while there is potential upside from Onyx's drug palbociclib (licensed to Pfizer (NYSE:PFE)), there are are also risks to Kyprolis from an increasingly competitive myeloma market, including Celgene's portfolio and Phase III drugs from Takeda and Bristol-Myers Squibb (NYSE:BMY).
The Bottom Line
All told, I believe Kyprolis can add $7 billion to $8 billion in net value to Amgen (net of the purchase price), assuming that Amgen can strip out at least half of Onyx's non-R&D operating expenses. The remainder of Onyx's portfolio and pipeline (again, excluding any hidden gems in preclinical development) is likely worth around $500 million to $1.5 billion. Relative to a pre-deal enterprise value of $81.5 billion for Amgen, then, this deal is worthwhile and value-additive, but again not a transformative event.
Amgen share's jumped 9% in early trading. The company is likely to continue to face pointed questions regarding its ability to leverage past deals, but the company does appear to be following a coherent strategy of lower-risk building block deals.
Disclosure – At the time of writing, the author did not own shares of any company mentioned in this article.

Related Articles
  1. Stock Analysis

    The Top 10 Small-Cap Stocks for 2016 (ATI, ARCB)

    Discover the top 10 small-cap stocks expected to grow in 2016, complete with summaries and growth outlooks for each company and its expected price target.
  2. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  3. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  4. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  5. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  6. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  7. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  8. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  9. Stock Analysis

    Forest Laboratories: An Activist Investment Analysis

    Find out how patience and perseverance paid off big-time for billionaire activist Carl Icahn during his four-year fight with Forest Laboratories.
  10. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. How long does it take to execute an M&A deal?

    Even the simplest merger and acquisition (M&A) deals are challenging. It takes a lot for two previously independent enterprises ... Read Full Answer >>
Trading Center